The Hematologic Impact of Umbilical Cord Milking Versus Deferred Cord Clamping in Premature Neonates.

The Hematologic Impact of Umbilical Cord Milking Versus Deferred Cord Clamping in Premature Neonates. A Randomized Controlled Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03147846

Enrollment

200

Registered

2017-05-10

Start date

2017-06-08

Completion date

2019-09-01

Last updated

2020-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delayed Cord Clamping, Preterm Neonates, Umbilical Cord Milking

Brief summary

Comparing the beneficial effect of cord milking versus deferred cord clamping in preterm neonates. A randomized controlled trial

Detailed description

Placental transfusion either by deferred cord clamping or umbilical cord milking became standard care and recommended management especially in preterm deliveries.1 In average, about 80 ml of blood was found to be transferred to the neoborn by one minute after birth.2 This additional blood can afford extra iron and blood volume giving the benefit of less iron deficiency anemia during the first year of life, less need for blood transfusion, less need for vasopressors and less intraventricular hemorrhage (IVH) by 50%.3 Placental transfusion with different techniques proved safety with no significant risks regarding postpartum hemorrhage, polycythemia, jaundice, Apgar score or admission rates.4 Our study aims to compare delayed cord clamping with umbilical cord milking as the best way for placental transfusion for preterm neonates.

Interventions

PROCEDUREdelayed cord clamping

delay of cord clamping for 60 seconds

PROCEDUREcord milking

active cord milking 5 times

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Outcomes Assessor)

Masking description

closed envelop method

Eligibility

Sex/Gender

ALL

Age

24 Weeks to 35 Weeks

Healthy volunteers

Yes

Inclusion criteria

• Gestational age 24 to 34+6 weeks

Exclusion criteria

* Category III CTG * Monochorionic twins * Significant antepartum hemorrhage * IUGR or Rh incompatibility

Design outcomes

Primary

Measure	Time frame	Description
hematological parameters of the premature neonates	12 months	first draw and peak hematocrit value and hemoglobin percent, need for inotropes and blood transfusion

Secondary

Measure	Time frame	Description
composite neonatal morbidities	12 month	incidence of intraventricular hemorrhage, necrotizing enterocolitis, retinopathy, jaundice, sepsis , patent ductus arteriosus, etc

Countries

Saudi Arabia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026